|
|
Post by #NoMoreNeedles on Jan 17, 2019 15:28:16 GMT -5
Would have liked seeing a refer-a-friend program approach, but not sure whether FDA allows this kind of approach.
|
|
|
|
Post by mnkdfann on Jan 17, 2019 15:42:29 GMT -5
Two enquires/opinions. 1. Since Symphony uses rx numbers from pharmacies, will these new program rxs be excluded from the weekly Friday numbers? 2. Would be nice if MNKD, once the 1000 people are enrolled to put out a PR. Something like 1000 people were enrolled in under 1 week. Scripts had better increase significantly (up by at least several hundred) over the next 3 to 4 months, or shorts will be screaming how Mannkind cannot even (practically) give it (Afrezza) away. If Eagle is not reporting the new scripts to Symphony, then Mannkind should make that known so shorts do not misrepresent the script numbers being released each week. And I had a Big Pharma conspiracy thought. If BP is as active at hurting Mannkind and frustrating Afrezza's acceptance as some claim, is it remotely possible for agents / puppets of BP to sign up for many (if not most) of the 1000 registrations in order to keep them out of the hands of those they were really meant for? |
|
|
|
Post by longliner on Jan 17, 2019 15:47:00 GMT -5
Two enquires/opinions. 1. Since Symphony uses rx numbers from pharmacies, will these new program rxs be excluded from the weekly Friday numbers? 2. Would be nice if MNKD, once the 1000 people are enrolled to put out a PR. Something like 1000 people were enrolled in under 1 week. Scripts had better increase significantly (up by at least several hundred) over the next 3 to 4 months, or shorts will be screaming how Mannkind cannot even (practically) give it (Afrezza) away. If Eagle is not reporting the new scripts to Symphony, then Mannkind should make that known so shorts do not misrepresent the script numbers being released each week. And I had a Big Pharma conspiracy thought. If BP is as active at hurting Mannkind and frustrating Afrezza's acceptance as some claim, is it remotely possible for agents / puppets of BP to sign up for many (if not most) of the 1000 registrations in order to keep them out of the hands of those they were really meant for? If that was the case and it was confirmed, I believe Shkreli would have some company. |
|
|
|
Post by sportsrancho on Jan 17, 2019 16:01:54 GMT -5
Not positive but I believe the 1000 is for new patients just like AT&T or Verizon offer, you can’t already be using the product. There would be no 1001, and they could do the same thing next year.
|
|
|
|
Post by tingtongtung on Jan 17, 2019 16:11:22 GMT -5
Just wondering the costs associated with this. Knowledgeable ones, please chime in.
What's the per unit cost for MNKD, and the resulting loss (profit?) because of these 1000 patients? I'm not talking about the associated benefits, just the pure profit/loss because of this. If they can lose less money, can they push more of this than the sales people?
Also, if they want to sell more Afrezza, they have to buy more Insulin from Amphastar. How much would that cost?
Please let this be the break that MNKD needs! I will buy more again :-)
|
|
|
|
Post by mannmade on Jan 17, 2019 16:16:54 GMT -5
They have all the insulin they can use for quite some time from Amph. In fact in last cc Mike spoke of renegotiating the amph deal to make more favorable. Also all the overseas deals are being done mostly to absorb insulin inventory and allow for productions costs to average down as volume increases.
|
|
|
|
Post by boca1girl on Jan 17, 2019 17:14:02 GMT -5
Someone (Mike C) at MNKD needs to contact Congressman Elijah Cummings, well in advance of his hearing with big pharma,, to explain our direct purchase program and the need for it. He needs to understand the pricing issues with the middle men, exclusivity w/rebates, and the costs associated with developing new drugs. Mike should explain in painful detail the 2 CLR’s and Martin Shirelli’s influence with the FDA that almost killed Afrezza.
|
|
|
|
Post by mnkdfann on Jan 17, 2019 17:19:11 GMT -5
Someone (Mike C) at MNKD needs to contact Congressman Elijah Cummings, well in advance of his hearing with big pharma,, to explain our direct purchase program and the need for it. He needs to understand the pricing issues with the middle men, exclusivity w/rebates, and the costs associated with developing new drugs. Mike should explain in painful detail the 2 CLR’s and Martin Shirelli’s influence with the FDA that almost killed Afrezza. Other pharmas also have programs. Lilly Cares for instance provides free medications to many, and (AFAIK) does not limit it to 1000 patients. |
|
|
|
Post by boca1girl on Jan 17, 2019 17:27:05 GMT -5
Someone (Mike C) at MNKD needs to contact Congressman Elijah Cummings, well in advance of his hearing with big pharma,, to explain our direct purchase program and the need for it. He needs to understand the pricing issues with the middle men, exclusivity w/rebates, and the costs associated with developing new drugs. Mike should explain in painful detail the 2 CLR’s and Martin Shirelli’s influence with the FDA that almost killed Afrezza. Other pharmas also have programs. Lilly Cares for instance provides free medications to many, and (AFAIK) does not limit it to 1000 patients. Aren’t those programs based on financial need? I just helped my 88 year old Mom get Eliquis from BMY, but she had to qualify based on her income and the total cost of all her other prescriptions. This MNKD direct purchase program does not have a financial need justification. It’s just trying to give cash buyers a lower cost by going direct, bypassing the middle men. |
|
|
|
Post by od on Jan 17, 2019 17:27:55 GMT -5
Someone (Mike C) at MNKD needs to contact Congressman Elijah Cummings, well in advance of his hearing with big pharma,, to explain our direct purchase program and the need for it. He needs to understand the pricing issues with the middle men, exclusivity w/rebates, and the costs associated with developing new drugs. Mike should explain in painful detail the 2 CLR’s and Martin Shirelli’s influence with the FDA that almost killed Afrezza. Other pharmas also have programs. Lilly Cares for instance provides free medications to many, and (AFAIK) does not limit it to 1000 patients. This is not a Patient Assistance Program such as Lilly Cares or similar programs from all pharmaceutical companies -- www.cms.gov/medicare/prescription-drug-coverage/prescriptiondrugcovgenin/papdata.html |
|
|
|
Post by kc on Jan 17, 2019 17:32:07 GMT -5
Other pharmas also have programs. Lilly Cares for instance provides free medications to many, and (AFAIK) does not limit it to 1000 patients. Aren’t those programs based on financial need? I just helped my 88 year old Mom get Eliquis from BMY, but she had to qualify based on her income and the total cost of all her other prescriptions. This MNKD direct purchase program does not have a financial need justification. It’s just trying to give cash buyers a lower cost by going direct, bypassing the middle men. My Mother is also on Eliquis and it is very costly. Hits the Donut hole and then she pays until out of the Donut hole. Big bugs for that drug. |
|
|
|
Post by od on Jan 17, 2019 17:33:18 GMT -5
Not positive but I believe the 1000 is for new patients just like AT&T or Verizon offer, you can’t already be using the product. There would be no 1001, and they could do the same thing next year. Thanks Sports. Limiting the direct purchase program to 1000 patients does not align with --- “It is important for MannKind to help those whose lives depend on insulin, and, unfortunately, over 65,000 uninsured or under-insured patients today must pay cash for their insulin each month, typically at the pharmacy counter at prices that reflect the costs of the pharmaceutical distribution chain,” said Michael Castagna, Chief Executive Officer of MannKind." |
|
|
|
Post by boca1girl on Jan 17, 2019 17:49:00 GMT -5
Not positive but I believe the 1000 is for new patients just like AT&T or Verizon offer, you can’t already be using the product. There would be no 1001, and they could do the same thing next year. Thanks Sports. Limiting the direct purchase program to 1000 patients does not align with --- “It is important for MannKind to help those whose lives depend on insulin, and, unfortunately, over 65,000 uninsured or under-insured patients today must pay cash for their insulin each month, typically at the pharmacy counter at prices that reflect the costs of the pharmaceutical distribution chain,” said Michael Castagna, Chief Executive Officer of MannKind."Maybe we can’t afford to allow more than 1000 at this point. I will bet that many of these 1000 participants will not be new to Afrezza. MNKD will probably be making less $$$ from these 1000 direct purchasers vs the traditional sales channel. I am all for lowering the price dramatically and driving volume but it’s probably a difficult balancing act. |
|
|
|
Post by od on Jan 17, 2019 17:54:13 GMT -5
Thanks Sports. Limiting the direct purchase program to 1000 patients does not align with --- “It is important for MannKind to help those whose lives depend on insulin, and, unfortunately, over 65,000 uninsured or under-insured patients today must pay cash for their insulin each month, typically at the pharmacy counter at prices that reflect the costs of the pharmaceutical distribution chain,” said Michael Castagna, Chief Executive Officer of MannKind."Maybe we can’t afford to allow more than 1000 at this point. I will bet that many of these 1000 participants will not be new to Afrezza. MNKD will probably be making less $$$ from these 1000 direct purchasers vs the traditional sales channel. I am all for lowering the price dramatically and driving volume but it’s probably a difficult balancing act. If this is a straight-out marketing play, then it is exploiting the un/underinsured to get press. Good for the 1000 patients who benefit from Afrezza, but to me the positioning is disingenuous. |
|
|
|
Post by goyocafe on Jan 17, 2019 18:07:49 GMT -5
What would it take for Mannkind to act as it’s own pharmacy? It’s a completely naive question, but curious if that is restricted by the FDA or other factors.
|
|
